Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2024 04:00 ET | Source: ENA Respiratory

ENA Respiratory Receives USPTO Notice of Allowance for Key Patent Covering INNA-051, a First-in-Class Antiviral Innate Immunomodulator

MELBOURNE, Australia, May 08, 2024 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated...
April 29, 2024 04:00 ET | Source: ENA Respiratory

ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 - a First-in-Class Antiviral Innate Immunomodulator

MELBOURNE, Australia, April 29, 2024 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated...
September 11, 2023 06:30 ET | Source: ENA Respiratory

New Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral Clearance

– INNA-051 increased early expression of multiple antiviral effector genes compared with placebo and shortened viral shedding duration in participants with confirmed influenza infection MELBOURNE,...
August 29, 2023 08:00 ET | Source: ENA Respiratory

ENA Respiratory Expands Leadership Team and Extends U.S. Department of Defense Funding to Enable Phase II Program of INNA-051 in Community-Acquired Viral Respiratory Infections

-- New $3.8 million DOD contract extension will fund non-clinical safety studies to support a three-month seasonal prophylaxis Phase 2b study in at-risk populations, comprising elderly individuals...
February 13, 2023 08:00 ET | Source: ENA Respiratory

Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study

-- Post hoc analyses found a statistically significant reduction in the duration of flu infection and a dose-related trend toward a reduction in symptom duration. -- These results support the further...
January 30, 2023 08:00 ET | Source: ENA Respiratory

Survey demonstrates that individuals with COPD seek more options to reduce risks of seasonal respiratory viral infections

-- ENA Respiratory and COPD Foundation survey confirms patients are overwhelmingly positive about taking an immune-modulating nasal spray to reduce lung disease exacerbations---- Survey was conducted...
January 09, 2023 08:00 ET | Source: ENA Respiratory

ENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051

-- Goal is to add new medical countermeasure (MCM) against known and emerging viral respiratory threats MELBOURNE, Australia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Clinical-stage pharmaceutical company...
May 11, 2022 08:00 ET | Source: ENA Respiratory

ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray

SYDNEY, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for...
March 15, 2022 08:00 ET | Source: ENA Respiratory

First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray

ENA Respiratory begins influenza challenge study for fast-acting nasal spray INNA-051, designed to boost innate immunity in patients at high risk of severe complications from respiratory infections ...
February 23, 2022 08:00 ET | Source: ENA Respiratory

ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray

-- INNA-051 is being developed to stimulate innate immunity and reduce the incidence and severity of respiratory viral infections, such as COVID-19, rhinovirus, or influenza in populations at-risk of...